Greenwich Lifesciences Inc

NASDAQ:GLSIUnited States

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of GP2, immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2)/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer. It has commenced a Phase III clinical trial, Flamingo-01 an immunotherapy to prevent breast cancer recurrences.

Contact Information

Headquarters

3992 Bluebonnet Dr, Building 14STAFFORD, TX, United States 77477

Phone

203-434-3290

Fax

302-636-5454

Executives

Independent Chairman of the Board

David Mcwilliams

Chief Executive Officer, Chief Financial Officer, Director

Snehal Patel

Vice President - Clinical & Regulatory Affairs

Jaye Thompson

Chief Medical Officer, Director

F. Joseph Daugherty

Independent Director

Kenneth Hallock